Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 18, 2015

View Archived Issues

Long-term data for olokizumab in rheumatoid arthritis

Tolerability of pevonedistat with docetaxel, paclitaxel/carboplatin or gemcitabine

Otsuka Pharmaceutical reviews highlights of third quarter 2015

Antibe licenses Knight Therapeutics rights for pain and inflammation drugs

MGB Biopharma completes feasibility study of topical MGB-BP-3

Cinfa Biotech treats first subjects with biosimilar pegfilgrastim

ProMetic reveals agent under development for diabetic nephropathy

First-in-patient data for anti-fractalkine MAb E-6011 in RA

Phase I results for FPA-008 in RA

Pfizer discloses antineoplastic compounds

Roche patents TAAR1 ligands

Medshine Discovery presents ROCK inhibitors

Shanghai Institute Materia Medica divulges KCNQ2 activators

Jiangsu Kanion Pharmaceutical and Medshine Discovery report anti-EV71 compounds

Genoscience's first-in-class autophagy inhibitor GNS-561

Tragara and Lee's Pharma to develop TG-02 in China and South East Asia

Genentech opts-in to the Ophthotech/Novartis ex-U.S. agreement for Fovista

European Commission approves expanded uses of Kalydeco for cystic fibrosis

Turing initiates phase I trial of TUR-004 for epileptic encephalopathies

Gemphire Therapeutics presents preclinical and clinical data for gemcabene

Phase II results with hepcortespenlisimut-L in HCC lead to phase III trial

Vigilant Biosciences receives CE mark for OncAlert oral cancer CD44/total protein lab test

MRG-106 enters phase I trial in patients with CTCL

Depomed licenses rights to Gruenenthal's analgesic cebranopadol

Actinium files IND for phase III trial of Iomab-B

Summit Therapeutics and University of Oxford extend utrophin collaboration

FDA grants orphan drug designation to Amyndas Pharmaceuticals' Compstatin 40

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...